Accent Capital Management’s Novo Nordisk NVO Stock Holding History

Accent Capital Management’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-550	Closed	-$28K	–	368
2025 Q4	$28K	Buy	550 +182	+49%	+$9.31K	0.01%	117
2025 Q3	$20.4K	Sell	368 -421	-53%	-$24.6K	0.01%	150
2025 Q2	$54.5K	Buy	789 +147	+23%	+$10K	0.02%	90
2025 Q1	$45.3K	Buy	642 +274	+74%	+$22.6K	0.03%	97
2024 Q4	$31.7K	Hold	368	–	–	0.02%	92
2024 Q3	$43.8K	Hold	368	–	–	0.03%	100
2024 Q2	$52.5K	Buy	368 +194	+111%	+$25.7K	0.03%	89
2024 Q1	$22.5K	Hold	174	–	–	0.02%	97
2023 Q4	$18K	Buy	+174	New	+$17.2K	0.01%	140

Other funds holding NVO

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

DAM

Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Accent Capital Management's NVO Position: Q1 2026 in Review

Accent Capital Management sold out of Novo Nordisk (NVO) in Q1 2026, closing a stake of 550 shares — an estimated $28K sold.

Accent Capital Management first reported a position in NVO in Q4 2023 and held it in 9 quarters. The position peaked at $54.5K in Q2 2025. 1,272 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

Accent Capital Management reported no remaining Novo Nordisk position as of Q1 2026 after selling out during the quarter.
Accent Capital Management sold 550 Novo Nordisk shares in Q1 2026, an estimated $28K.
Accent Capital Management first reported a position in Novo Nordisk in Q4 2023 and held it in 9 quarters.
Accent Capital Management's Novo Nordisk position peaked at $54.5K in Q2 2025.
1,272 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Accent Capital Management's 13F filing for Q1 2026, filed 11 May 2026.